Background Risks for cardiovascular diseases, including myocardial infarction and stroke,
are elevated in people with HIV infection (PWH). However, no trials of statin utilization with …

Objectives Despite an increased risk of atherosclerotic cardiovascular disease (ASCVD) in
people living with HIV (PLWH), a gap in statin prescribing practices has been described for …

Background Individuals with human immunodeficiency virus (HIV) face elevated
cardiovascular disease (CVD) risk. There are limited data regarding the application of the …

Antiretroviral therapy (ART) has been a lifeline for untold numbers of patients with HIV. But
as mounting evidenceshowstheinfectionmayincreasetheir risk of cardiovascular disease …

Abstract Objectives Using the American College of Cardiology/American Heart Association
2013 atherosclerotic cardiovascular disease (ASCVD) management guidelines, we …

Background. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections
are associated with increased risk of cardiovascular disease (CVD). The potential impact of …

The widespread availability of highly effective antiretroviral therapies has reduced mortality
from opportunistic infections in persons living with HIV (PLHIV), resulting in an increase in …

Background: Recent studies suggest that statins are underprescribed in patients living with
HIV (PLWH) at risk for atherosclerotic cardiovascular disease (ASCVD), but none have …

Background People with HIV have increased atherosclerotic cardiovascular disease
(ASCVD) risk, worse outcomes following incident ASCVD, and experience gaps in …

Background Expanding statin use may help to alleviate the excess burden of atherosclerotic
cardiovascular disease in people living with HIV (PLHIV). Pravastatin and pitavastatin are …